Literature DB >> 9950272

Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.

O S Gudmundsson1, G M Pauletti, W Wang, D Shan, H Zhang, B Wang, R T Borchardt.   

Abstract

UNLABELLED: To evaluate the cellular permeation characteristics and the chemical and enzymatic stability of coumarinic acid-based cyclic prodrugs 1 and 2 of the opioid peptides [Leu5]-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH) and DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH), respectively.
METHODS: The rates of conversion of the cyclic prodrugs 1 and 2 to [Leu5]-enkephalin and DADLE, respectively, in HBSS, pH 7.4 (Caco-2 cell transport buffer) and in various biological media having measurable esterase activity were determined by HPLC. The cell permeation characteristics of [Leu5]-enkephalin, DADLE and cyclic prodrugs 1 and 2 were measured using Caco-2 cell monolayers grown onto microporus membranes and monitored by HPLC.
RESULTS: In HBSS, pH 7.4, cyclic prodrugs 1 and 2 degraded chemically to intermediates that further degraded to [Leu5]-enkephalin and DADLE, respectively, in stoichiometric amounts. In 90% human plasma and rat liver homogenate, the disappearance of cyclic prodrugs 1 and 2 was significantly faster than in HBSS, pH 7.4. The half-lives in 90% human plasma and in rat liver homogenate were substantially longer after pretreatment with paraoxon, a known inhibitor of serine-dependent esterases. When applied to the AP side of a Caco-2 cell monolayer, cyclic prodrug 1 exhibited significantly greater stability against peptidase metabolism than did [Leu5]-enkephalin. Cyclic prodrug 2 and DADLE exhibited similar stability when applied to the AP side of the Caco-2 cell monolayer. Prodrug 1 was 665-fold more able to permeate the Caco-2 cell monolayers than was [Leu5]-enkephalin, in part because of its increased enzymatic stability. Prodrug 2 was shown to be approximately 31 fold more able to permeate a Caco-2 cell monolayer than was DADLE.
CONCLUSIONS: Cyclic prodrugs 1 and 2, prepared with the coumarinic acid promoiety, were substantially more able to permeate Caco-2 cell monolayers than were the corresponding opioid peptides. Prodrug 1 exhibited increased stability to peptidase metabolism compared to [Leu5]-enkephalin. In various biological media, the opioid peptides were released from the prodrugs by an esterase-catalyzed reaction, which is sensitive to paraoxon inhibition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950272     DOI: 10.1023/a:1018828207920

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-09-15       Impact factor: 15.470

2.  The barrier function of CYP3A4 and P-glycoprotein in the small bowel.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-09-15       Impact factor: 15.470

3.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

Review 4.  Recent developments in the design of receptor specific opioid peptides.

Authors:  V J Hruby; C A Gehrig
Journal:  Med Res Rev       Date:  1989 Jul-Sep       Impact factor: 12.944

5.  Carboxypeptidase A. Differences in the mechanisms of ester and peptide hydrolysis.

Authors:  D S Auld; B Holmquist
Journal:  Biochemistry       Date:  1974-10-08       Impact factor: 3.162

6.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability.

Authors:  I J Hidalgo; T J Raub; R T Borchardt
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

7.  Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.

Authors:  B Wang; K Nimkar; W Wang; H Zhang; D Shan; O Gudmundsson; S Gangwar; T Siahaan; R T Borchardt
Journal:  J Pept Res       Date:  1999-04

8.  The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides.

Authors:  O S Gudmundsson; S D Jois; D G Vander Velde; T J Siahaan; B Wang; R T Borchardt
Journal:  J Pept Res       Date:  1999-04

9.  Opioid peptide interactions with lipid bilayer membranes.

Authors:  V Ramaswami; R C Haaseth; T O Matsunaga; V J Hruby; D F O'Brien
Journal:  Biochim Biophys Acta       Date:  1992-08-24

10.  Effects of the ester moiety on stereoselective hydrolysis of several propranolol prodrugs in rat tissues.

Authors:  K Takahashi; S Tamagawa; H Sakano; T Katagi; N Mizuno
Journal:  Biol Pharm Bull       Date:  1995-10       Impact factor: 2.233

View more
  11 in total

1.  Highly Constrained Bicyclic Scaffolds for the Discovery of Protease-Stable Peptides via mRNA Display.

Authors:  David E Hacker; Jan Hoinka; Emil S Iqbal; Teresa M Przytycka; Matthew C T Hartman
Journal:  ACS Chem Biol       Date:  2017-02-01       Impact factor: 5.100

Review 2.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 3.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

4.  A Novel Peptide Restricts Ethanol Modulation of the BK Channel In Vitro and In Vivo.

Authors:  Luisa L Scott; Sangeetha Iyer; Ashley E Philpo; Melva N Avalos; Natalie S Wu; Ted Shi; Brooke A Prakash; Thanh-Tu Nguyen; S John Mihic; Richard W Aldrich; Jonathan T Pierce
Journal:  J Pharmacol Exp Ther       Date:  2018-08-29       Impact factor: 4.030

5.  Enhanced activity of cyclic transporter sequences driven by phase behavior of peptide-lipid complexes.

Authors:  Kun Zhao; Uh-Joo Choe; Daniel T Kamei; Gerard C L Wong
Journal:  Soft Matter       Date:  2012       Impact factor: 3.679

6.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.

Authors:  O S Gudmundsson; K Nimkar; S Gangwar; T Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

10.  Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.

Authors:  A Bak; O S Gudmundsson; G J Friis; T J Siahaan; R T Borchardt
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.